Seattle Genetics, the modern cancer research Center

Seattle Genetics is the fastest growing cancer research Center in the United States. The company’s only commercialized drug Adcetris has made the company even more famous, earning it profits of up to $226 million. Adcetris is commonly used to fight lymphomas and is currently being tested against various types of lymphomas. With Takeda Pharmaceuticals, Seattle’s partner company, trying to sell Adcetris outside Canada and the United States, profits accrued are expected to increase.

Seattle Genetics big plans

Adcetris is not the only drug developed by Seattle Genetics; the firm is developing other 12 cancer-fighting drugs. According to Seattle Genetics CEO, the company plans to introduce another drug, 33A, into phase 3 clinical trials. The drug is expected to treat acute myeloid leukemia. The company is also finalizing the development of three other drugs: two are used to treat cancer of the bladder and one that treats breast cancer.

Seattle Genetics has major plans; aside from introducing new drugs, the company plans to increase their workforce. It estimated that 100 people would be hired in the United States branches and 20 in Switzerland, making it 120 people. Seattle Genetics already has 800 employees – increase in the workforce will result in an increase in annual output.

Dr. Siegall’s educational background and work experience

Dr. Clay Siegall obtained his bachelor’s degree in Zoology from the University of Maryland and his doctoral degree in genetics from George Washington University. Dr. Siegall is the founder and the CEO of Seattle Genetics since 1998. He is also part of the board of directors of Seattle Genetics. Dr. Siegall educational background clearly states that he is a trained researcher and his primary interest is in cancer therapies. Therefore, he has capitalized on his professional expertise to develop antibody-drug conjugates (ADC’s) for treatment of cancer.

Dr. Siegall has over the years served as a director of the board of directors for various companies such as Ultragenyx Pharmaceuticals, Mirna Therapeutics, Inc., and Alder Biopharmaceuticals Inc. Before Seattle Genetics was formed, he used to work for Bristol-Myers Squibb Pharmaceutical Research Institute. He also worked for the National Cancer Institute and National Institutes of Health. With his work experience, he has been able to run activities at Seattle Genetics smoothly.